Scarica l'app Stockscreener
113.75
5.81%
6.22
Dopo l'orario di chiusura:
113.90
0.15
+0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$107.53
Aprire:
$109.475
Volume 24 ore:
2.18M
Relative Volume:
1.34
Capitalizzazione di mercato:
$22.73B
Reddito:
$5.36B
Utile/perdita netta:
$1.43B
Rapporto P/E:
16.09
EPS:
7.0718
Flusso di cassa netto:
$1.42B
1 W Prestazione:
+15.84%
1M Prestazione:
+17.17%
6M Prestazione:
+13.65%
1 anno Prestazione:
+60.68%
Intervallo 1D:
$109.47
$115.56
Intervallo di 1 settimana:
$99.79
$115.56
Portata 52W:
$66.83
$115.56
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
113.76 | 21.48B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
490.70 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.17 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.48 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-02-05 | Iniziato | H.C. Wainwright | Buy |
| 2026-01-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
UBS raises Incyte stock price target to $113 on biotech recovery - Investing.com
Incyte Corporation stock hits 52-week high at 112.32 USD - Investing.com
Incyte stock jumps on positive EU review for eczema cream - Investing.com
Star Therapeutics' bleeding-disorder drug VGA039 gets full Phase 1/2 data spotlight - Stock Titan
Incyte (INCY) Receives Positive CHMP Opinion for Opzelura Approval - GuruFocus
Incyte wins EU step toward first steroid-free eczema cream - Stock Titan
Incyte extends hematology data at EHA, shares track NASDAQ biotech peers - Ad-hoc-news.de
Japan Approves Incyte Lymphoma Therapy, Expanding DLBCL Options - MyChesCo
Incyte stock: Is INCY outperforming the healthcare sector? - MSN
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on Medicaid settlement - Investing.com
H.C. Wainwright reiterates Incyte stock rating on Medicaid settlement By Investing.com - Investing.com Canada
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more - MSN
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT - MSN
Truist raises Incyte stock price target to $105 on VWD outlook - Investing.com UK
Incyte reports tafasitamab combo benefit in Phase III FrontMIND study - MSN
Incyte Corporation’s Stock Price Soars to $103.66, Marking a Robust 5.54% Uptick - Smartkarma
Why is Incyte stock gaining today? - Investing.com
Incyte Corporation (INCY) Reaches Settlement with CMS Over Medic - GuruFocus
INCY Upgraded by BMO Capital -- Price Target Raised to $94.00 - GuruFocus
Incyte settles Medicaid rebate litigation with CMS, expects $246 million benefit - Investing.com
Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules - StreetInsider
Incyte reaches CMS settlement, to record $246M non-cash benefit after Opzelura ruling - TradingView
BMO upgrades Incyte stock rating on strategic progress By Investing.com - Investing.com South Africa
Incyte Stock: Is INCY Outperforming the Healthcare Sector? - Barchart.com
Incyte (INCY) Secures Approval for Minjuvi in Japan - GuruFocus
Incyte Trial Data Support New First-Line Approach in Lymphoma - MyChesCo
Incyte StockStifel lifts price target after bile duct disease data - AD HOC NEWS
Incyte secures Japanese approval for lymphoma drug Minjuvi - grafa.com
Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Japan clears Incyte’s Minjuvi for relapsed DLBCL patients - Stock Titan
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - Yahoo Finance Singapore
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock underperforms Monday when compared to competitors - MSN
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - Yahoo Finance
Incyte Corp (INCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Incyte Corp (INCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Incyte Corp (INCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Incyte Corp (INCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Incyte Corp (INCY) Institutional Confidence - TradingKey
Incyte Corp (INCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Incyte Corp (INCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Incyte Corp (INCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Incyte's Vega deal adds VGA039 with $1 billion sales potential by 2034 - S&P Global
Incyte to buy Vega Therapeutics in hematology deal worth up to $2B - MSN
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Pfizer (PFE) and MBX Biosciences, Inc. (MBX) - The Globe and Mail
Incyte slides as investors digest updated INCA033989 (mutCALR) data and a cautious analyst take - Quiver Quantitative
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):